Albireo Pharma Sells Bylvay-Associated PRV For $105M

by Vandana Singh, Benzinga Editor

September 7, 2021 11:04 AM | 1 min read |

Albireo Pharma Inc ALBO has agreed to sell its Priority Review Voucher (PRV) for $105 million.
The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).
Related Content: Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US.
The net sales proceeds expected from the transaction are in addition to the $186.3 million in cash, cash equivalents, and short-term investments Albireo reported as of June 30, 2021.
Price Action: ALBO shares are down 0.24% at $29.60 during the market session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.